With a one year PEG ratio of 0.84, Myriad Genetics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 19.62% of US stocks.
Over the past twelve months, MYGN has reported earnings growth of -680.94%, putting it ahead of only 2.84% of US stocks in our set.
In terms of volatility of its share price, MYGN is more volatile than 79.98% of stocks we're observing.
Stocks that are quantitatively similar to MYGN, based on their financial statements, market capitalization, and price volatility, are HBIO, KVHI, DSS, CCUR, and DHX.
MYGN's SEC filings can be seen here. And to visit Myriad Genetics Inc's official web site, go to myriad.com.
Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.
Myriad Genetics (MYGN) announces the launch of a new patient home collection kit for its GeneSight Psychotropic test.Patient DNA for the assay is collected with a cheek swab. Afterward, the patient puts the swab in a prepaid pre-addressed shipping envelope for transport back to Myriad for testing....
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, today announced the launch of a new patient home collection kit for the GeneSight® Psychotropic test. The kit allows the DNA sample collection typically administered in a clinician’s office to be completed at home. The new direct-to-patient collection kit must still be ordered by a licensed healthcare provider.
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced today that a new study published in Future Medicine demonstrates the ability of myPath® Melanoma to accurately classify skin lesions ruled indeterminate by standard pathological review. “This validation study for myPath Melanoma demonstrates the ability of the test to accurately classify lesions which are ruled indeterminate by an expert dermatopathologist,” said Nicole Lambert, president of Myriad International, Oncology and Women’s Health. “Importantly, this accuracy was linked to the gold standard endpoint of real world clinical outcomes demonstrating the accuracy of the myPath Melanoma test result for patients and physicians concerned about this deadly cancer.”